| Date Filed | Type | Description |
| 06/12/2023 |
4
| Stehman-Breen Catherine (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.|
Txns:
| Granted 29,532 options to buy
@ $7.12, valued at
$210.3k
|
|
| 06/12/2023 |
4
| Stehman-Breen Catherine (Director) has filed a Form 4 on Generation Bio Co.|
Txns:
| Granted 25,000 options to buy
@ $4.83, valued at
$120.8k
|
|
| 05/25/2023 |
4
| Stehman-Breen Catherine (Director) has filed a Form 4 on Dyne Therapeutics, Inc.|
Txns:
| Granted 24,900 options to buy
@ $13.49, valued at
$335.9k
|
|
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/29/2021 |
3
| Stehman-Breen Catherine (Director) has filed a Form 3 on Tenaya Therapeutics, Inc. |
| 06/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2021 |
4
| Stehman-Breen Catherine (Director) has filed a Form 4 on Dyne Therapeutics, Inc.|
Txns:
| Granted 19,596 options to buy
@ $19.56, valued at
$383.3k
|
|
| 09/23/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/16/2020 |
3
| Stehman-Breen Catherine (Director) has filed a Form 3 on Dyne Therapeutics, Inc. |
| 06/18/2020 |
4
| Stehman-Breen Catherine (Director) has filed a Form 4 on Generation Bio Co.|
Txns:
| Converted 5,062 shares
@ $0
Converted 8,942 preferred shares
@ $0 |
|
| 06/15/2020 |
4
| Stehman-Breen Catherine (Director) has filed a Form 4 on Generation Bio Co.|
Txns:
| Granted 52,000 options to buy
@ $19, valued at
$988k
|
|
| 06/11/2020 |
3
| Stehman-Breen Catherine (Director) has filed a Form 3 on Generation Bio Co. |
| 04/05/2017 |
4
| Stehman-Breen Catherine (SVP, Chief Medical Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $29.7, valued at
$3M
|
|
| 04/05/2017 |
3
| Stehman-Breen Catherine (SVP, Chief Medical Officer) has filed a Form 3 on Sarepta Therapeutics, Inc. |